CTLA4 and neoplasm: Preliminary results from the phase 1 clinical trial (NCT00790010) showed that Ipilimumab (CTLA-4 antibody) plus Bevacizumab (VEGF inhibitors) in patients with metastatic melanoma (MM) had favorable clinical outcomes, for reasons of increasing tumor vascular expression of ICAM-1 and VCAM-1 and lymphocyte infiltration in tumors (89).